Figure 4.

Virologic efficacy of remdesivir vs placebo. A, Differences in mean daily rate of change of viral load among patients with moderate/severe disease by treatment arm. P values are shown for differences in adjusted daily rate of change when normalized to baseline level. For calculations, RNA values below the assay limit of quantification (LOQ) of 1.79 log₁₀ copies/mL were set as half the LOQ (1.49 log₁₀ copies/mL) when measurements were above the lower limit of detection (LLOD) and one-quarter the LOQ (1.19 log₁₀ copies/mL) when RNA was not detected. B, Bar plot of patients with increasing or persistently elevated viral loads measured through 5 days of treatment. Relative risk (RR) of an increasing viral load comparing remdesivir and placebo recipients are shown with corresponding P values.